STAT

STAT

AstraZeneca antibody reduced Covid-19 risk in immunocompromised
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Asking again! Could you tell us what you think of The Readout? Fill out
Opinion: Hurricane season is approaching fast. We need to talk about health care resilience
Extreme weather fueled by accelerating climate change puts patients, providers, and health care facilities at severe risk, jeopardizing lives. Unpredictable shifts in weather patterns are creating new regional extremes,
Opinion: H5N1 doesn't have to be a repeat of Covid-19's 'public health versus the economy'
The Biden administration announced new programs on May 10 to incentivize dairy farmers and workers to collaborate with public health efforts to investigate and mitigate the H5N1 avian influenza outbreak among dairy
STAT+: Data integrity watchdogs call for stronger safeguards in scientific journals
SAN FRANCISCO — According to Elisabeth Bik, a scientific watchdog who has discovered thousands of errors in scientific papers, the problem of fraud, errors, or data mishandling in the scientific literature seems
STAT+: To bolster global health, Wellcome Trust's new CEO thinks Big Tech should get involved
LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies. But to John-Arne Røttingen, the new head of the Wellcome Trust, one
Listen: Live! From the STAT Breakthrough Summit West
On this week’s “Readout LOUD,” we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that note, we chat with our AI
Amid backlash to harm reduction, addiction experts warn against reprising 'war on drugs'
SAN FRANCISCO — Amid what feels like an ever-worsening drug crisis here, locals and politicians alike are fed up. Overdose death rates remain near all-time highs. The Tenderloin, a historic downtown neighborhood,
STAT+: NVIDIA's Kimberly Powell touts progress on AI in drug discovery
SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug? The answer remains, ambiguously, “the future,” but at
STAT+: Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis
SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to
Second House panel advances two-year telehealth extension
WASHINGTON — A House subcommittee on Thursday advanced legislation that would extend some pandemic-era telehealth policies in Medicare for two years, bringing the panel’s approach in line with another
In military medicine, study shows rank and race affect care
Higher ranking military officers receive more resources and better care than low ranking military officers, according to an analysis of 1.5 million military ER visits published Thursday in the journal Science. The study
STAT+: Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peers
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis. But if you want to invent lots of potential drugs
WuXi Biologics beefs up its lobbying operation
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and
STAT+: PDS Biotech's survival benefit is absurdly overstated
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Hello, friends! I’m
STAT+: Pharmalittle: We're reading about a Roche obesity drug, an experimental Lilly insulin, and more
Top of the morning to you, and a fine one it is, despite the gray skies hovering over the Pharmalot campus again. Our spirits remain sunny, however, because we recall a bit of insight from the Morning Mayor, who taught
Opinion: As childhood asthma worsens, insurers restrict access to an essential medication
As pediatricians who take care of children in the inpatient, emergency, and primary care settings, we are alarmed by the recent trend of families having to go without basic medications to control their child’s
STAT+: Biogen, Ionis drop ALS treatment after study failure
A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program. In the randomized, 99-person
Blackstone wants in on red-hot immunology market
The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on results of a Phase 1/2 trial. Johnson & Johnson said
STAT+: Lilly's weekly insulin works as well as daily products, new studies show
Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by
STAT+: Obesity drug from Roche succeeds in early test, sending company shares up
LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.  The drug, a